Literature DB >> 1873815

Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells.

K Pantel1, G Schlimok, D Kutter, G Schaller, T Genz, B Wiebecke, R Backmann, I Funke, G Riethmüller.   

Abstract

An astoundingly high frequency of micrometastatic cells have been found in bone marrow aspirates of patients with colon carcinomas (G. Schlimok et al., J. Clin. Oncol., 8:831-837, 1990), although these tumors very rarely metastasize to the skeleton. This observation has raised questions about the malignant potential of such cells. In a first attempt to characterize this potential, we have assessed the expression of major histocompatibility complex (MHC) class I antigens on bone marrow micrometastases, inasmuch as down-regulation of these molecules is a potential mechanism to escape from MHC class I-restricted lysis by cytotoxic T-cells. The two groups of cancer patients compared were those with tumors known to rarely (stomach and colon cancer) or frequently (breast cancer) manifest skeleton metastases. Bone marrow aspirates taken from these patients were probed for individual disseminated tumor cells using the immunoalkaline phosphatase technique with monoclonal antibody CK2 to the epithelial differentiation antigen cytokeratin 18 (CK-18), as described previously (G. Schlimok et al., Proc. Natl. Acad. Sci. USA, 84:8672-8676, 1987). Specimens containing CK18-positive cells were colabeled with monoclonal antibody W6/32 directed to a framework (or nonpolymorphic) antigenic determinant of MHC class I heavy chains associated with beta 2-microglobulin. W6/32-positive CK-18-positive cells could be detected in 25 of 54 patients (46.3%) with significantly higher incidences in 26 breast cancer patients (61.9%) as compared to 28 patients with carcinomas of the stomach and colon (27.3 and 29.4%). Independent from the origin of the primary carcinoma, the incidence of W6/32-negative CK18-positive cells was positively correlated to both the differentiation grade of the primary tumor (P less than 0.05) and appeared to be linked to the occurrence of regional lymph node metastases (statistically not significant) determined by conventional histological examination. The present results demonstrate for the first time that down-regulation of MHC expression on individual micrometastatic cells correlates to the differential pattern of metastasis obtained by comparing breast and gastrointestinal carcinomas. This finding together with the suggestive link to clinical risk factors supports the significance of reduced MHC class I expression for the survival of residual metastatic cells which is a major determinant of prognosis for patients with solid tumors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1873815

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

Review 1.  The connectivity of lymphogenous and hematogenous tumor cell dissemination: biological insights and clinical implications.

Authors:  Jonathan P Sleeman; Blake Cady; Klaus Pantel
Journal:  Clin Exp Metastasis       Date:  2012-06-06       Impact factor: 5.150

2.  CD8+ T cells are crucial for the ability of congenic normal mice to reject highly immunogenic sarcomas induced in nude mice with 3-methylcholanthrene.

Authors:  M Boesen; I M Svane; A M Engel; J Rygaard; A R Thomsen; O Werdelin
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 3.  [Minimal residual tumor in gastrointestinal carcinoma. Relevance to prognosis and oncologic surgical consequences].

Authors:  S Gretschel; A Bembenek; T Schulze; W Kemmner; P M Schlag
Journal:  Chirurg       Date:  2006-12       Impact factor: 0.955

4.  Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes.

Authors:  Ilsa M Coleman; Jeffrey A Kiefer; Lisha G Brown; Tiffany E Pitts; Peter S Nelson; Kristen D Brubaker; Robert L Vessella; Eva Corey
Journal:  Neoplasia       Date:  2006-10       Impact factor: 5.715

5.  Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells.

Authors:  R Riesenberg; R Oberneder; M Kriegmair; M Epp; U Bitzer; A Hofstetter; S Braun; G Riethmüller; K Pantel
Journal:  Histochemistry       Date:  1993-01

Review 6.  The pan-therapeutic resistance of disseminated tumor cells: Role of phenotypic plasticity and the metastatic microenvironment.

Authors:  Bo Ma; Alan Wells; Amanda M Clark
Journal:  Semin Cancer Biol       Date:  2019-07-31       Impact factor: 15.707

7.  Confocal images of circulating tumor cells obtained using a methodology and technology that removes normal cells.

Authors:  Priya Balasubramanian; Liying Yang; James C Lang; Kris R Jatana; David Schuller; Amit Agrawal; Maciej Zborowski; Jeffrey J Chalmers
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

8.  Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.

Authors:  Tanja Fehm; Oliver Hoffmann; Bahriye Aktas; Sven Becker; Erich F Solomayer; Diethelm Wallwiener; Rainer Kimmig; Sabine Kasimir-Bauer
Journal:  Breast Cancer Res       Date:  2009-08-10       Impact factor: 6.466

9.  Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients.

Authors:  Sabine Riethdorf; Klaus Pantel
Journal:  Breast Cancer Res       Date:  2009-12-18       Impact factor: 6.466

10.  ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients.

Authors:  Tanja Fehm; Natalia Krawczyk; Erich-Franz Solomayer; Graziella Becker-Pergola; Silke Dürr-Störzer; Hans Neubauer; Harald Seeger; Annette Staebler; Diethelm Wallwiener; Sven Becker
Journal:  Breast Cancer Res       Date:  2008-09-15       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.